News | Ventricular Assist Devices (VAD) | July 09, 2015

Abiomed Announces Expansion of U.S. Headquarters

Maker of the Impella heart pumps expected to bring 100 new local jobs

Abiomed, U.S. headquarters expansion, Impella 2.5, RP, jobs

July 9, 2015 - During an event with Massachusetts Gov. Charlie Baker in June, Abiomed announced a major expansion of its U.S. headquarters in Danvers, Massachusetts, and the creation of approximately 100 new, local jobs.

Abiomed will lease an additional 85,000 square feet of space in a building adjacent to its current U.S. headquarters in Danvers. The added space will be dedicated to manufacturing and research.

The company currently has more than 600 employees, nearly half of which work in Massachusetts. Over the past two years, Abiomed has already added 150 jobs in the Commonwealth.

Duane Pinto, M.D., a cardiologist and director of the cardiac intensive care unit at Beth Israel Deaconess Medical Center, also attended the event at Abiomed's Danvers headquarters.

Plans for Abiomed's U.S. expansion follow two recent U.S. Food and Drug (FDA) approvals of its heart pump devices. Most recently, in March, Abiomed received a FDA Pre-Market Approval (PMA) for the Impella 2.5 heart pump to be using during elective and urgent high-risk percutaneous coronary intervention (PCI) procedures.

As many as 100,000 U.S. cardiac patients are turned down for heart surgery each year because the risks are too high, and the Impella 2.5 is approved for use to help patients maintain stable heart function and circulation during certain high-risk procedures.

In January, Abiomed's Impella RP (Right Percutaneous) System received FDA approval under a Humanitarian Device Exemption (HDE). The Impella RP is a single access right-sided percutaneous ventricular assist device and is FDA indicated for providing circulatory assistance to pediatric or adult patients who develop acute right heart failure or decompensation for up to 14 days.

For more information:

Related Content

Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Overlay Init